KORVITIN REDUCES THE HIGH MAINTENANCE OF MYELOPEROXIDASE IN PLASMA OF BLOOD OF PATIENTS WITH THE ACUTE INFARCT OF MYOCARDIUM.

We studied the content of myeloperoxidase in plasma of blood, which is a new additional marker of the metabolic activity of phagocytes and the activity of inflammation in patientes with the acute infarct of myocardium and possibility of its correction of Korvitin. We inspected 15 practically healthy persons in which the content of myeloperoxidase was 74,5±16,3 ng/ml, 13 patients with a stable stenocardia (the conent of myeloperoxidase was 218,4±30,9 ng/ml) and 60 patients with acute infarct of myocardium (the content of myeloperoxidase was 606,0±59,3 ng/ml at the beginning of therapy) in the dynamics of treatment. In patients accepting standard treatment (without application of Korvitin), the content of myeloperoxidase was unchanged during 7 days of treatment. It patients administered korvitin, the action of this preparation depended on the initial level of myeloperoxidase. In Patients with the initial normal plasma content of myeloperoxidase (16,7%), its content insignificantly increased during the time course of the treatment, while in patients with the high initial level of myeloperoxidase (83,3%), its level declined during treatment.